The Keio University-backed digital medicine developer has secured $19.3m from a consortium including several Japanese corporations.

Japan-based medical treatment app provider CureApp has raised ¥2.1bn ($19.3m) from investors including corporates Dai-ichi Life, Itochu, Koshidaka and Toyoshima & Co, taking its total funding to roughly $58.8m.
Financial services firms Shoko Chukin Bank and Sumitomo Mitsui Banking Corporation (SMBC) also took part in the round, as did Healthcare Innovation, Saisei Ventures and Sumitomo Mitsui Trust Investment’s Japan Co-Investment III.
Insurer Dai-ichi Life and holding group Koshidaka participated directly, while conglomerate Itochu, textile trader Toyoshima & Co…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in